NCT04623541 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT04623541
Title	Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome (EPCORE™ CLL-1)
Acronym	EPCORE™ CLL-1
Recruitment	Recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Genmab
Indications	Richter's syndrome chronic lymphocytic leukemia/small lymphocytic lymphoma chronic lymphocytic leukemia diffuse large B-cell lymphoma
Therapies	Epcoritamab-bysp Epcoritamab-bysp + Venetoclax Cyclophosphamide + Doxorubicin + Epcoritamab-bysp + Prednisone + Rituximab + Vincristine Sulfate Epcoritamab-bysp + Lenalidomide
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| NLD \| ITA \| ISR \| GBR \| FRA \| ESP \| DNK \| DEU \| CZE \| BEL \| AUS

No variant requirements are available.